Johnson & Johnson says its coronavirus vaccine is effective against delta variant

July 2, 2021: According to a small study, the Johnson & Johnson Corona virus vaccine provides effective protection against the Delta variant, which is offering hope to many developing economies facing a summer surge of the highly contagious strain.

The company, based in New Brunswick, NJ, said blood samples were taken from eight vaccinators who participated in the laboratory study, which showed that Johnson and Johnson’s single dose shot produced an immune response against Delta Variant. (Results were not peer-reviewed.) Earlier, clinical trials showed that the vaccine provided 66% protection against symptomatic infections.

“We believe that our vaccine offers durable protection against COVID-19 and elicits neutralizing activity against the Delta variant,” Paul Stoffels, chief scientific officer at Johnson & Johnson, said in a news release. “This adds to the robust body of clinical data supporting our single-shot vaccine’s ability to protect against multiple variants of concern.”

Statistics so far show that all three vaccines approved by the United States provide effective protection against all known forms of the virus. An analysis by British health officials, highlighting data from a large pool of people, indicates that Pfizer-Biotech Messenger RNA vaccine Delta varies 96% against hospital admissions.

Moderna also announced Tuesday that its MRNA vaccine has seen a “slight decrease” in effective antibodies against Delta variants compared to actual strains. A large-scale case study reviewed by the Food and Drug Administration indicates that the moderna vaccine offers 94.1% protection against infection from the strain discovered in Wuhan, China.

There have been rising concerns about how much protection vaccines provide against the highly virulent delta strain, which the World Health Organization said has been detected in almost 100 countries. Health authorities in the Seychelles on Thursday said six fully vaccinated people in one of the world’s most inoculated nations, which has been combating a delta variant surge, had died of the covid-19. Those people had received either an Indian-made version of the Oxford-AstraZeneca vaccine or Sinopharm shots.

About 12 million doses of the Johnson & Johnson shot, which is based on similar technology as the Oxford-AstraZeneca vaccine, have been administered in the United States. Because only one dose is required for protection — though there has been talk of booster shots — the relatively cheap Johnson & Johnson vaccine had been seen as a potential lifeline for developing countries, which have borne the brunt of the delta variant.

Johnson & Johnson announced in May that it would be providing 200 million doses to Covax, the global initiative to distribute vaccines equitably. In recent weeks, the Biden administration has dispatched 5.5 million doses of the company’s vaccine to Brazil, where the virus has wreaked havoc, and Colombia.

There have been reports that the number of people receiving the Johnson & Johnson vaccine has dropped dramatically, prompting the United States to briefly suspend its rollout in April. Following a safety review, the CDC and FDA lifted the suspension.

Stay tuned to BaaghiTV for latest news and Updates!